geographic region were as follows (dollar amounts in millions):
The increase in global Repatha
sales for 2024 was primarily driven by volume growth of 43%, partially offset by lower net selling price of 10%.
The increase in global Repatha
sales for 2023 was driven by volume growth, partially offset by lower net selling price.
65
For 2025, we expect lower declines in net selling price.
For a discussion of ongoing litigation related to Repatha, see Part IV—Note 20, Contingencies and commitments, to the Consolidated Financial Statements.
Otezla
Total Otezla sales by geographic region were as follows (dollar amounts in millions):
The decrease in global Otezla
sales for 2024 was primarily driven by lower net selling price of 8%, partially offset by volume growth of 3%. For 2025, we expect Otezla to follow the historical pattern of lower sales in the first quarter relative to subsequent quarters due to the impact of benefit plan changes, insurance reverification and increased co-pay expenses as U.S. patients work through deductibles. In January 2025, Otezla was selected by CMS for Medicare price setting that will be applicable beginning on January 1, 2027.
The decrease in global Otezla
sales for 2023 was driven by lower net selling price and inventory, partially offset by volume growth.
TEPEZZA
Total TEPEZZA sales by geographic region were as follows (dollar amounts in millions):
* Change in excess of 100%
N/A = not applicable
TEPEZZA was acquired on October 6, 2023 from our Horizon acquisition and generated $1.9 billion and $448 million in product sales for 2024 and 2023, respectively. As TEPEZZA was acquired on October 6, 2023, there were no recorded product sales in the periods prior to the acquisition date.
EVENITY
Total EVENITY sales by geographic region were as follows (dollar amounts in millions):
The increases in global EVENITY sales for 2024 and 2023 were driven by volume growth.
66
KYPROLIS
Total KYPROLIS sales by geographic region were as follows (dollar amounts in millions):
The
increase in global KYPROLIS
sales for 2024 was driven by volume growth outside the United States.
The increase in global KYPROLIS sales for 2023 was driven by volume growth.
Nplate
Total Nplate sales by geographic region were as follows (dollar amounts in millions):
Global Nplate sales for 2024 decreased 1% and included U.S. government orders of $128 million and $286 million for 2024 and 2023, respectively. Excluding the U.S. government orders from this comparison, global Nplate sales increased 12% for 2024, driven by volume growth of 8% and higher net selling price of 6%.
The increase in global Nplate sales for 2023 was primarily driven by volume growth, including U.S. government orders totaling $286 million.
Aranesp
Total Aranesp sales by geographic region were as follows (dollar amounts in millions):
Global Aranesp sales for 2024 remained relatively unchanged as unfavorable changes to both estimated sales deductions and foreign currency exchange rates were offset